Study shows considerable efficacy result on weight loss in patients
LeptiCore® is a unique proprietary natural formulation which have been shown to have properties which could be beneficial to weight loss in obese and people are overweight.
One of the latest study for weight loss on the use of LeptiCore shows considerable efficacy result. This study, The use of LeptiCore® in reducing fat gain and managing weight loss in patients with metabolic syndrome, was done with involves 92 obese, and divided into three groups for 8 weeks. Group 1 takes placebo, Group 2 takes LeptiCore formula A = 1 capsule (300 mg each) and Group 3 takes LeptiCore formula B = 2 capsules (300 mg each).
Here is the result taken from the study:
Body weight (Table11)
Although the placebo group showed virtually no change (0.82 kg) in body weight over the 8-week trial, the Formula A group lost 5.2 kg (p < 0.001), and the Formula B group lost 6.6 kg (p < 0.001). In terms of intra-group mean-% change from baseline (Initial) to 8 weeks, the placebo, Formula A and Formula B groups lost 0.82%, 5.4% (p < .05), and 6.95% (p < 0.001), respectively.
Body fat (Table22)
As with body weight, the placebo group showed little (0.1%) change in mean %-body fat after 8 weeks whereas the Formula A group lost 1.1% (p < 0.05), and the Formula B group lost 1.8% (p < 0.05). In terms of intra-group mean % change from baseline to 8 weeks, the placebo, Formula A and Formula B groups lost 0.24%, 2.8% (p < 0.05), and 4.1% (p < 0.001), respectively.
Waist size (Table33)
Waist circumference is one of the most important determinants in the diagnosis of obesity and metabolic syndrome. In this case, the Formula A and Formula B groups showed a 4.6 cm and 5.6 cm decrease, respectively, vs. the 0.6 cm decrease demonstrated by the placebo group (p < 0.05). In terms of intra-group mean % change in waist size from baseline to 8 weeks, the placebo, Formula A and Formula B groups lost 0.57%, 4.4% (p < 0.05), and 4.6% (p < 0.001), respectively.
Hip size (Table44)
Once again, although the placebo group showed virtually no change (0.4 cm), the Formula A group lost 4.4 cm (p < 0.05), and the Formula B group lost 5.6 cm (p < 0.05) in circumference over the 8-week trial. In terms of intra-group mean % change from baseline to 8 weeks, the placebo, Formula A and Formula B groups lost 0.32%, 3.5% (p < .05), and 4.6% (p < 0.001), respectively.
In addition to body weight, during this study, LeptiCore also shows reductions in triglyceride, blood glucose, CRP and serotonin levels.
300mg of LeptiCore can be found in each serving of TLS® CORE Fat & Carb Inhibitor and daily intake of 600mg of LeptiCore is the same as the amount of LeptiCore is used as Formula B in the study.
